Table 1.
Baseline characteristics of patients enrolled in the study
| Characteristics | KTR (n = 743) | Control group (n = 94) |
|---|---|---|
| Age, yrs | 58 [50–68] | 53.5 [44–60] |
| Males, n (%) | 471 (63.4%) | 27 (28.7%) |
| BMI, kg/m2 | 25.3 [23.0–27.7] | |
| Re-transplants, n (%) | 59 (8%) | |
| Donor type | ||
| DBD | 652 (87.8%) | |
| Living | 91 (12.2%) | |
| Median time since transplantation, yrs | 10 [5–16] | |
| Median eGFR (ml/min/1.73m2) | 54.1 [38.8–73.6] | |
| Primary kidney disease, n (%) | ||
| Glomerular | 198 (26.7%) | |
| Vascular | 20 (2.7%) | |
| Polycystic kidney disease | 87 (11.6%) | |
| Diabetes | 225 (30.3%) | |
| Cakut | 67 (8.9%) | |
| Kidney stone | 11 (1.5%) | |
| Other | 135 (18.3%) | |
| Maintenance immunosuppressive therapy, n (%) | ||
| Calcineurin inhibitors | 680 (91.6%) | |
| Antimetabolitea | 563 (75.9%) | |
| Steroids | 660 (88.9%) | |
| mTORi | 224 (15.1%) | |
| Comorbidities, n (%) | ||
| Hypertension | 645 (86.9%) | |
| T2D | 88 (11.9%) | |
| CVD | 75 (10.1%) | |
DBD Donation after Brain Death, eGFR estimated Glomerular Filtration Rate (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation), CAKUT Congenital Anomalies of the Kidney, mTORi Mammalian target of rapamycin inhibitors, T2D type 2 diabetes, CVD Cardiovascular disease
aIncludes mycophenolate mofetil, mycophenolic acid, or azathioprine